Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Return on Sales (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Return on Sales for 7 consecutive years, with 61.74% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales fell 15234.0% year-over-year to 61.74%, compared with a TTM value of 0.36% through Dec 2025, down 225691.0%, and an annual FY2025 reading of 0.36%, changed N/A over the prior year.
  • Return on Sales was 61.74% for Q4 2025 at Keros Therapeutics, down from 0.52% in the prior quarter.
  • Across five years, Return on Sales topped out at 15885.0% in Q1 2021 and bottomed at 5410.0% in Q3 2023.
  • Average Return on Sales over 5 years is 382.16%, with a median of 3.13% recorded in 2025.
  • The sharpest move saw Return on Sales surged 1588781bps in 2021, then crashed -1588634bps in 2022.
  • Year by year, Return on Sales stood at 0.39% in 2021, then tumbled by -1080bps to 4.58% in 2022, then crashed by -7000bps to 324.86% in 2023, then skyrocketed by 128bps to 90.6% in 2024, then tumbled by -168bps to 61.74% in 2025.
  • Business Quant data shows Return on Sales for KROS at 61.74% in Q4 2025, 0.52% in Q3 2025, and 1.69% in Q2 2025.